How the speed of face aging measures biological age and predicts cancer outcomes

Competing interests: R.H.M. reports being on an Advisory Board for ViewRay and AstraZeneca; Consulting for AstraZeneca, Pfizer, Varian Medical Systems, and Sio Capital Management; Honorarium from Novartis and Springer Nature; and Research Funding from the National Institute of Health, ViewRay, AstraZeneca, Siemens Medical Solutions USA, Inc., and Varian Medical Systems. DSB reports Editorial, unrelated to this work: Associate Editor of Radiation Oncology, HemOnc.org (no financial compensation); Research funding, unrelated to this work: American Cancer Society, American Society for Radiation Oncology, National Institutes of Health; Advisory and consulting, unrelated to this work: Mercurial AI. H.J.W.L.A. reports advising and consulting for Onc.AI, Love Health, Sphera, Editas, AstraZeneca, and Bristol Myers Squibb, unrelated to this work. B.H.K. reports research funding from the Botha-Chan Low Grade Glioma Consortium (National Institutes of Health [NIH]-USA K08DE030216-01). F.H., R.H.M., and H.J.W.L.A. report that Mass General Brigham has filed provisional patents on two next-generation facial health algorithms, including FaceAge (US Provisional Application No. 63/769,840). G.L., J.H., A.W., D.B., P.J.C., V.P., S.P., and C.G. declare no competing interests.